Wednesday, September 9, 2026
60 articles analyzed
Updated Sep 9, 8:37 PM · 60 sources analyzed
Key Takeaways
Novo Nordisk's CagriSema Phase 3 in basal-insulin T2D patients completed; data readout is the next critical catalyst for the asset.
Merck's LEAP-012 Phase 3 HCC trial terminated, removing a high-profile TACE-combination strategy from the competitive landscape.
Wave Life Sciences' WVE-004 ALS extension terminated, adding to doubts about the stereopure RNA platform in neurological diseases.
🏆 Winner
Novo Nordisk — CagriSema Phase 3 completion in a key T2D subpopulation keeps the regulatory timeline intact and the differentiation story credible.
📉 Loser
Merck — termination of the LEAP-012 Phase 3 in HCC marks a concrete pipeline setback in a high-value oncology indication.
🔭 Watch Next
MoonLake Immunotherapeutics' Phase 2 sonelokimab data in hidradenitis suppurativa — expected at EADV or ACR in late 2026 — is the most commercially consequential readout visible in today's sources.
Novo Nordisk CagriSema Phase 3 in T2D Completed
Novo Nordisk's Phase 3 trial evaluating CagriSema — a fixed-dose combination of cagrilintide and semaglutide — for blood sugar and weight reduction in type 2 diabetes patients on basal insulin has completed, per ClinicalTrials.gov. No efficacy or safety data have been released publicly from this registry update alone, but the trial's completion signals that a data readout is approaching for one of the most closely watched combination GLP-1 assets in development. CagriSema's differentiated mechanism — pairing an amylin analog with a GLP-1 agonist — positions it as a potential best-in-class weight and glycemic control agent in a market already crowded by Lilly's orforglipron and tirzepatide.
ClinicalTrials.gov ↗Merck Sharp & Dohme (Merck)
Lenvatinib + Pembrolizumab (LEAP-012) in Incurable/Non-metastatic Hepatocellular Carcinoma
The LEAP-012 Phase 3 trial (NCT04246177) evaluating lenvatinib plus pembrolizumab in combination with TACE (transarterial chemoembolization, a procedure that delivers chemotherapy directly to liver tumors via their blood supply) has been terminated, per ClinicalTrials.gov. No efficacy or safety data were disclosed in this registry record.
Why it matters
The LEAP-012 termination is a meaningful setback for Merck's HCC franchise ambitions, particularly in the intermediate-stage segment where TACE remains standard of care; it raises questions about whether the lenvatinib-pembrolizumab backbone can deliver incremental benefit when added to locoregional therapy versus systemic use alone. Investors should watch whether Merck redirects HCC development resources to alternative LEAP combinations or concedes this segment.
What to watch
Watch for Merck's next HCC pipeline disclosure — either at ASCO GI or in a quarterly pipeline update — clarifying whether any LEAP-program successor is planned for the intermediate-stage population.
Novo Nordisk
CagriSema in Type 2 Diabetes (on basal insulin)
Trial status updated to Completed on ClinicalTrials.gov. Detailed efficacy and safety data have not yet been released; full numerical results are expected at a future medical meeting or publication.
Why it matters
The trial's completion keeps CagriSema on track for a regulatory package that could differentiate Novo Nordisk in the insulin-experienced T2D segment, where competitors have less data. Investors will want to know whether glycemic and weight outcomes in this harder-to-treat population match the headline REDEFINE results before updating peak sales assumptions.
What to watch
Watch for a data presentation at a major diabetes congress — likely ADA or EASD in the next one to two quarters — that will provide the first efficacy and safety numbers from this basal-insulin population.
Eli Lilly and Company
Orforglipron in Obesity or Overweight with Type 2 Diabetes
Trial status updated to Completed on ClinicalTrials.gov. The registry update reflects study closure; no efficacy or safety figures have been disclosed in this record.
Why it matters
With a completed Phase 3 dataset in hand, Lilly's regulatory team can now consolidate the orforglipron package; the oral delivery format is the key commercial differentiator versus injectable competition, and T2D labeling data will be essential for payer coverage decisions. The investment thesis hinges on whether weight loss magnitude in T2D patients is competitive with tirzepatide's own bar.
What to watch
Watch for Lilly's NDA submission announcement for orforglipron, expected within the next two to three quarters, and any conference data cut showing head-to-head weight and HbA1c outcomes.
Merck Sharp & Dohme (Merck)
Favezelimab + Pembrolizumab (MK-4280A) in PD-(L)1-refractory Classical Hodgkin Lymphoma
Trial status updated to Completed on ClinicalTrials.gov. This was a randomized study of co-formulated favezelimab (LAG-3 inhibitor) plus pembrolizumab versus physician's choice chemotherapy; no efficacy or safety results have been publicly disclosed from this registry record.
Why it matters
Merck has invested heavily in favezelimab as a backbone combination partner for pembrolizumab, and this refractory Hodgkin lymphoma dataset will be a key read on whether LAG-3 inhibition adds meaningful benefit beyond PD-1 re-challenge alone. Without numerical data, it is impossible to assess competitive positioning against CD30-directed or antibody-drug conjugate approaches, but the data package will matter for label strategy.
What to watch
Watch for a data presentation at ASH 2026 or a peer-reviewed publication that discloses ORR (the share of patients whose tumors shrank) and durability of response versus chemotherapy.
Trial status updated to Completed on ClinicalTrials.gov. Detailed efficacy and safety data have not yet been released; full numerical results are expected at a future medical meeting or publication.
Why it matters
Completion of this basal-insulin cohort fills a critical data gap for CagriSema's profile — showing whether the combo works on top of existing insulin therapy matters enormously for real-world prescribing and formulary positioning against tirzepatide and upcoming oral GLP-1s.
Analysis
The trial's completion keeps CagriSema on track for a regulatory package that could differentiate Novo Nordisk in the insulin-experienced T2D segment, where competitors have less data. Investors will want to know whether glycemic and weight outcomes in this harder-to-treat population match the headline REDEFINE results before updating peak sales assumptions.
What to watch
Watch for a data presentation at a major diabetes congress — likely ADA or EASD in the next one to two quarters — that will provide the first efficacy and safety numbers from this basal-insulin population.
Trial status updated to Completed on ClinicalTrials.gov. The registry update reflects study closure; no efficacy or safety figures have been disclosed in this record.
Why it matters
Orforglipron is Lilly's oral small-molecule GLP-1 candidate — a completed Phase 3 in the T2D-obesity overlap population moves it closer to an NDA submission and would directly compete with Novo Nordisk's oral semaglutide and the broader injectable GLP-1 market.
Analysis
With a completed Phase 3 dataset in hand, Lilly's regulatory team can now consolidate the orforglipron package; the oral delivery format is the key commercial differentiator versus injectable competition, and T2D labeling data will be essential for payer coverage decisions. The investment thesis hinges on whether weight loss magnitude in T2D patients is competitive with tirzepatide's own bar.
What to watch
Watch for Lilly's NDA submission announcement for orforglipron, expected within the next two to three quarters, and any conference data cut showing head-to-head weight and HbA1c outcomes.
Trial status updated to Completed on ClinicalTrials.gov. This was a randomized study of co-formulated favezelimab (LAG-3 inhibitor) plus pembrolizumab versus physician's choice chemotherapy; no efficacy or safety results have been publicly disclosed from this registry record.
Why it matters
LAG-3 plus PD-1 combinations are being tested across multiple tumor types; a completed randomized Phase 2 dataset in PD-(L)1-refractory Hodgkin lymphoma — a population with very limited options — could validate or challenge the combination strategy in this setting.
Analysis
Merck has invested heavily in favezelimab as a backbone combination partner for pembrolizumab, and this refractory Hodgkin lymphoma dataset will be a key read on whether LAG-3 inhibition adds meaningful benefit beyond PD-1 re-challenge alone. Without numerical data, it is impossible to assess competitive positioning against CD30-directed or antibody-drug conjugate approaches, but the data package will matter for label strategy.
What to watch
Watch for a data presentation at ASH 2026 or a peer-reviewed publication that discloses ORR (the share of patients whose tumors shrank) and durability of response versus chemotherapy.
The LEAP-012 Phase 3 trial (NCT04246177) evaluating lenvatinib plus pembrolizumab in combination with TACE (transarterial chemoembolization, a procedure that delivers chemotherapy directly to liver tumors via their blood supply) has been terminated, per ClinicalTrials.gov. No efficacy or safety data were disclosed in this registry record.
Why it matters
TACE-based combination strategies in intermediate-stage HCC have become increasingly crowded and competitive; termination of LEAP-012 removes one of the higher-profile immuno-oncology plus locoregional therapy combinations from the field and cedes ground to competing approaches including those from AstraZeneca and Bristol Myers Squibb.
Analysis
The LEAP-012 termination is a meaningful setback for Merck's HCC franchise ambitions, particularly in the intermediate-stage segment where TACE remains standard of care; it raises questions about whether the lenvatinib-pembrolizumab backbone can deliver incremental benefit when added to locoregional therapy versus systemic use alone. Investors should watch whether Merck redirects HCC development resources to alternative LEAP combinations or concedes this segment.
What to watch
Watch for Merck's next HCC pipeline disclosure — either at ASCO GI or in a quarterly pipeline update — clarifying whether any LEAP-program successor is planned for the intermediate-stage population.
Phase 2 trial evaluating sonelokimab (a nanobody targeting IL-17A and IL-17F) versus placebo in hidradenitis suppurativa has been marked Completed on ClinicalTrials.gov. Full efficacy data including HiSCR response rates (the standard measure of lesion reduction in this disease) have not been disclosed in this registry record.
Why it matters
Hidradenitis suppurativa is a chronic, debilitating skin disease with very limited approved therapies; sonelokimab's dual IL-17A/F blockade via a compact nanobody format is a differentiated mechanism, and data from this trial will determine whether MoonLake can credibly compete against secukinumab and bimekizumab.
Analysis
MoonLake's entire investment thesis rests on sonelokimab's ability to show superior or competitive response rates in HS versus existing IL-17 inhibitors; the trial's completion means Phase 2 data are imminent, and this is the most important near-term catalyst for the company's valuation. The nanobody format — smaller than a conventional antibody and potentially more tissue-penetrant — is the scientific rationale for expecting differentiated efficacy, but investors need actual numbers before that thesis holds.
What to watch
Watch for MoonLake's Phase 2 data disclosure at a dermatology or rheumatology congress — likely EADV or ACR in late 2026 — showing HiSCR50 and HiSCR75 rates and the safety profile versus placebo.
Allosteric Pathways Govern G Protein Coupling Selectivity at Promiscuous GPCRs
A bioRxiv preprint characterizes the structural allosteric pathways that determine which G protein subtypes a promiscuous GPCR (a cell-surface receptor that can activate multiple intracellular signaling partners) preferentially engages, providing a mechanistic basis for receptor-biased signaling.
Why it matters
Understanding these allosteric selectivity determinants could enable rational design of ligands that preferentially activate therapeutically beneficial G protein pathways while avoiding those that drive side effects — a long-standing goal for GPCR drug discovery in cardiovascular, CNS, and metabolic disease.
Analysis
GPCR-targeted drugs represent the single largest drug class by revenue, yet most act without pathway selectivity; if this structural framework proves generalizable, it gives medicinal chemists a new handle for designing biased agonists (drugs that activate only selected downstream signals) with improved therapeutic windows. This is early-stage academic science, but the GPCR drug development community — including companies like Structure Therapeutics and Escient Pharmaceuticals — will be watching for experimental validation.
What to watch
Watch for peer-reviewed publication and independent experimental validation of the proposed allosteric models, which would be the prerequisite for translating these findings into a structure-based drug design campaign.
Wave Life Sciences Terminates WVE-004 ALS/FTD Open-Label Extension
Wave Life Sciences' open-label extension study of WVE-004 — an RNA-targeting therapy for C9orf72-associated ALS (a genetic form of the fatal motor neuron disease) and frontotemporal dementia — has been terminated, per ClinicalTrials.gov.
Why it matters
C9orf72 repeat expansion is the most common genetic cause of ALS and FTD, making it a high-priority target; termination of the WVE-004 extension suggests the program did not meet the bar needed to continue long-term follow-up, which narrows the field of RNA-targeting approaches in this genetically defined population.
Analysis
Wave Life Sciences had positioned stereopure oligonucleotide chemistry as a differentiated platform for CNS diseases, but repeated setbacks — including earlier WVE-004 phase 1 signals that were underwhelming — raise serious questions about whether the platform's tolerability and target engagement are sufficient for ALS applications. Competitors including Ionis Pharmaceuticals and uniQure, which are pursuing antisense and gene therapy approaches in the same genetic population, will benefit from reduced head-to-head noise.
What to watch
Watch for Wave Life Sciences' next pipeline update or investor day, where management will need to articulate which, if any, neurological programs remain viable for the company's stereopure RNA platform.
Debiopharm Afabicin Bone and Joint Infection Phase 2 Terminated
Debiopharm's Phase 2 trial of afabicin — an antibiotic targeting bacterial fatty acid synthesis (FASII), a pathway distinct from existing antibiotics — for Staphylococcal bone and joint infections has been terminated, per ClinicalTrials.gov.
Why it matters
FASII inhibitors represented a conceptually attractive new antibiotic class for drug-resistant Staphylococcal infections, including MRSA; termination of this study is a setback for the class and leaves bone and joint infection — an area with high rates of treatment failure and surgical morbidity — without a novel mechanism in late-stage development.
Analysis
Bone and joint infections are notoriously difficult to treat due to biofilm formation and poor antibiotic penetration into bone, and the termination of a randomized Phase 2 in this setting likely reflects either efficacy or enrollment challenges that make the risk-benefit case for continued investment difficult to justify. For antibiotic drug developers watching this space, the result reinforces the high bar for demonstrating superiority or non-inferiority in surgical infection trials.
What to watch
Watch for any Debiopharm public communication explaining the reason for termination — whether efficacy, safety, or strategic — which will clarify whether afabicin has any remaining development path in other Staphylococcal indications.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.
Every weekday morning
Start your morning with the stories moving biotech.
Clinical readouts · FDA watch · Deal flow · Pipeline pulse